New Zealand markets closed
  • NZX 50

    11,684.81
    -129.53 (-1.10%)
     
  • NZD/USD

    0.6174
    -0.0085 (-1.35%)
     
  • NZD/EUR

    0.6145
    -0.0054 (-0.86%)
     
  • ALL ORDS

    7,358.70
    +1.00 (+0.01%)
     
  • ASX 200

    7,114.50
    +1.70 (+0.02%)
     
  • OIL

    89.91
    -0.59 (-0.65%)
     
  • GOLD

    1,760.30
    -10.90 (-0.62%)
     
  • NASDAQ

    13,242.90
    -263.09 (-1.95%)
     
  • FTSE

    7,550.37
    +8.52 (+0.11%)
     
  • Dow Jones

    33,706.74
    -292.30 (-0.86%)
     
  • DAX

    13,544.52
    -152.89 (-1.12%)
     
  • Hang Seng

    19,773.03
    +9.12 (+0.05%)
     
  • NIKKEI 225

    28,930.33
    -11.81 (-0.04%)
     
  • NZD/JPY

    84.5170
    -0.4640 (-0.55%)
     

Could This Be Moderna's Ticket to Long-Term Success?

·3-min read

Moderna (NASDAQ: MRNA) waited a long time to reach this important moment: the authorization of its vaccine in infants and children. This month, the FDA authorized the vaccine for both teens and children ages six months and older, and vaccine rollout has begun for the youngest group. Could this new authorization be Moderna's ticket to long-term success?

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting